Dr. Anna Belcheva completed her medical school and residency in Internal Medicine at the University of Texas. She then trained in Hematology/Oncology at MD Anderson Cancer Center in Houston, TX where she also did research in the field of angiogenesis with Dr. Lee Ellis.
Subsequently she practiced in Houston, TX first as managing partner at one of the largest groups in the city, Oncology Consultants PA and then went on to develop the Community Cancer Centers System for Houston Methodist Hospital.
Dr. Jeremy Bridge-Cook is currently Chief Scientific Officer and VP R&D at Genomadix Inc., a point of care PCR diagnostics company. Prior to this, Jeremy was President and CEO of Rna Diagnostics, a personalized cancer diagnostics company specializing in monitoring cancer therapy efficacy, where he raised $13 million in several financing rounds.
Prior to this, he worked at Luminex Corporation and Tm Bioscience (TMB, acquired by Luminex in 2007) for 16 years in positions of increasing responsibility.
Mark Girardi has over 30 years of experience in life sciences, in vitro diagnostics, and medical devices commercialization and reimbursement. He has experience in product management, sales, marketing, and strategy consulting. Mark is currently Principal, Head of In Vitro/Medical Diagnostics at IQVIA.
Previously, Mark held roles as a Partner with Clarivate DRG, leading the firm’s MedTech practice area, and as Senior Vice President at Boston Healthcare Associates where his focus was on the Medical Technology space working with clients in the medical device, diagnostics, and digital health areas.
Donna Polizio is currently at Bionano as the Global Head of Market Access. She has had a long career in the In-Vitro (IVD) and Laboratory Developed Tests (LDT) industry starting at Coulter Corporation in the early 1990s and then on to several diagnostic companies including Hologic, Redpath, Aureon.
She spent 11 years at Exact Sciences (formerly from Genomic Health) as the V.P. U.S. Managed Care and Reimbursement. During her time at Genomic Health, she managed payor contracting and reimbursements that helped drive the company to profitability prior to Exact Sciences acquisition in 2019.
Kim Popovits is committed to changing the paradigm of cancer care, Kim led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the over treatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare. She served as Genomic Health’s Chairman of the Board from 2012 thru 2019, and Chief Executive Officer and President from 2009 thru 2019.
Paul G. Smith is Chair & CEO of Rally Enterprises & Communications Corp., a Canadian cable operator. Over his career, he has held executive roles and served on the boards of directors of several companies across various industries. Currently, he is Chair of Park Lawn Corporation (TSX: PLC); Chair of Centralized Supply Chain Ontario (Supply Ontario), an agency charged with overseeing the province’s procurement practices; and Chair of the Audit Committee of BlueRush Inc. (TSXV: BTV).